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BrainNeuroferritinopathy or hereditary ferritinopathy is an inherited neurodegenerative disease caused bymutations
in ferritin light chain (FTL) gene. The clinical features of the disease are highly variable, and include a movement
disorder, behavioral abnormalities, and cognitive impairment. Neuropathologically, the disease is characterized
by abnormal iron and ferritin depositions in the central nervous system. We report a family in which
neuroferritinopathy begins with chronic headaches, later developing progressive orolingual and arm dystonia,
dysarthria, cerebellar ataxia, pyramidal tract signs, and psychiatric symptoms. In the absence of classic clinical
symptoms, the initial diagnosis of the disease was based on magnetic resonance imaging studies. Biochemical
studies on the proband showed normal serum ferritin levels, but remarkably low cerebrospinal ﬂuid (CSF) ferri-
tin levels. A novel FTLmutationwas identiﬁed in the proband. Our ﬁndings expand the genetic and clinical diver-
sity of neuroferritinopathy and suggest CSF ferritin levels as a novel potential biochemical marker for the
diagnosis of neuroferritinopathy.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Neuroferritinopathy or hereditary ferritinopathy [17] is an autoso-
mal dominant movement disorder caused by mutations in the ferritin
light chain (FTL) gene on chromosome 19q13.3. Neuropathologically,
the disease is characterized by the abnormal depositions of iron and
ferritin in the brain, particularly in the basal ganglia. Thus far, six different
mutations in exon four of the FTL gene have been reported, all affecting
the FTL polypeptide C-terminus [6,7,11,16,18,23]. Clinically, the disease
presents as amiddle-age-onset chorea and dystonia. Clinical presentation
may also include extrapyramidal and pyramidal tract signs as well as
cerebellar ataxia, dysautonomia, cognitive decline, and psychiatric
symptoms; however, the clinical presentation is highly variable
both within and between families [2,3,5,14,21,25]. Several in vitro ands supported by grants from the
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. This is an open access article underin vivo studies (reviewed in [17]) have implicated at least two key
toxic mechanisms in the pathogenesis of the disease: abnormal iron
metabolism and generation of free radicals, and abnormal ferritin
aggregation. These two mechanisms may be acting together to lead to
neurodegeneration and thus to the progression of the disease. The mu-
tant FTL polypeptide can cause deregulation of cellular ironmetabolism
(ferritin loss of function), oxidative stress, and overproduction of ferritin
polypeptides (a positive feedback loop), while excess iron and ferritin
could trigger the formation of ferritin aggregates, which may physically
interfere with normal cellular functions (gain of a toxic function) [24].
Herein, we report the identiﬁcation of a novel mutation in the FTL
gene in a Japanese family with neuroferritinopathy, and highlight the
utility of T2-weighted magnetic resonance imaging and biochemical
studies as potential biomarkers for the diagnosis of the disease.
2. Subjects and methods
2.1. Case report
The proband, a 44-year-old, right-handed Japanese female, presented
initially with chronic headaches at the age of 42. She was allergic to milk,
wheat, and eggs. There was no history of anoxia at birth or carbon mon-
oxide poisoning and no family history of neurodegenerative disorders orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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psychiatric disturbances such as emotional lability, and was diagnosed
with panic disorder at a mental health clinic. At the age of 44, she experi-
enced difﬁculty in speaking and walking as well as clumsiness in her left
arm. Neurological examination showed emotional incontinence, mild
cognitive decline (Full Scale Intelligence Quotient = 83, Verbal Intelli-
gence Quotient = 84, Performance Intelligence Quotient = 84), slurred
speech, bilateral hyperextensibility and hypotonus, left-sided cerebellar
ataxia, hyperreﬂexia, and extensor plantar response. Cranial nerve
examination showed slow eye saccades and involuntary movement of
tongue. Rigidity, spasticity, tremor, dystonia, chorea, and parkinsonism
were not observed initially. Her gait was unsteady (not wide-based);
she exhibited some difﬁculty during tandem gait. Gait disturbance
gradually progressed, and her gait became increasingly unsteady with a
tendency to fall. Limb weakness, sensory disturbance, and bladder or
rectal disturbances were not observed. Orthostatic hypotension was
detected by the head-up tilt test (blood pressure: 121/79 mm Hg in the
supine, 90/63 mm Hg in the standing position with dizziness). Several
months after the initial presentation, oromandibular, orolingual, and left
dominant arm dystonia, tongue dyskinesia, tongue wigglingmovements,
tongue biting, and dysphagia developed. Her serum ferritin levels were
20 ng/mL (normal range, 5–204 ng/mL). Serum levels of iron, copper,
ceruloplasmin, hemoglobin, and vitaminEwerenormal. Routine hemato-
logical studies and thyroid function studies were also normal. No tumor
markers or autoimmune antibodies such as anti-glutamic acid decarbox-
ylase and anti-gliadin were detected. An abdominal computed tomogra-
phy (CT)/MRI showed the presence of a left ovarian cyst; however, tests
for paraneoplastic antibodies such as anti-Hu and anti-Yo in serum and
CSF were negative. Analysis of CSF revealed a remarkably low ferritin
level (b1.00 ng/mL, normal range: 6.68 ± 0.93 ng/mL). Several medica-
tions, including trihexyphenidyl, benzodiazepine, valproate, and muscle
relaxants, were attempted; however, they did not improve the patient's
symptoms. Herbal medicine (Shakuyaku-kanzo-to) relieved the left
ﬁnger hyperextensibility due to dystonia.
2.2. Methods
MRI, laboratory tests including measurement of serum ferritin levels
and genetic analysiswere performed on the proband andher family (par-
ents and brother). CSF ferritin levels were alsomeasured on the proband.
Brain MRI was performed using a 1.5-Tesla system (GyroscanAchieva;
Philips Medical Systems, Best, The Netherlands). T1-weighted (TR =
600 ms, TE = 12 ms), T2-weighted (TR = 4423 ms, TE = 100 ms), and
T2*-weighted (TR = 640 ms, TE = 23 ms) sequences were acquired in
the transverse plane. In the proband, susceptibility-weighted imaging
(SWI) based on 3-dimensional T1-weighted fast ﬁeld echo (3DT1FFE)Fig. 1. A. Pedigree of the family. The square symbols represent males and the circle symbols
deceased individuals. The numbers under the symbols represent current age. B. MRI of the proand 123I-iodoamphetamine (IMP) single photon emission tomography
(IMP-SPECT) were also performed.
After informed consent was obtained, genomic DNA was extracted
from a 500 μL saliva aliquot collected with the Oragene Discover Collec-
tion Kit (DNAgenotek, Ottawa, Canada) using prepIT-C2DGenomicDNA
MiniPrep Kit (Oragene) in accordance with the manufacturer's instruc-
tions. PCR ampliﬁcation was performed on 0.15 μg of genomic DNA to
amplify all four exons of the FTL gene using the oligonucleotide primer
pairs: Exon 1 (352 bp) F: 5′-ACGTCCCCTCGCAGTTCGGCGG-3′ and R:
5′-GGAGGTGCGCAGCTGGAGG-3′; Exon 2 (327 bp) F: 5′-GGTAAACA
GAGGGCGGAGTC-3′ and R: 5′-ACCGAACTCAATCTCCCAGA-3′; and
Exons 3 & 4 (660 bp) F: 5′-TGTAGGTTTAGTTCTATGTG-3′ and R:
5′-AAGCCCTATTACTTTGCAAG-3′; at 2 mmol of each oligonucleotide,
200 μmol dNTPs, and 1.5 mM MgCl2 in a 50 μL reaction solution, and
cycled for 35 cycles of 94 °C for 30 s, 45 °C for 45 s, and 72 °C for 45 s.
DNA fragments were separated on a 1% agarose gel and visualized by
ethidium bromide staining, and the corresponding bands excised and
puriﬁed using the GeneJET Gel Extraction Kit (Thermo Scientiﬁc,
Lithuania). DNA sequencing was performed in both directions as
described [23] using CEQ 8000 GeXP Genetic Analysis System and
Software (Beckman Coulter). Ampliﬁcation products of exons 3 and 4
were also subcloned into pCR 2.1 vector (Invitrogen, Carlsbad, CA) and
transformed into One Shot® TOP10 Chemically Competent E. coli cells
(Invitrogen) according to the manufacturer's protocol. Recombinant
plasmid DNA was isolated from 10 clones of different PCR reactions
and sequenced in both directions as described [23].3. Results
3.1. Imagining studies
Brain MRI of the proband showed symmetrical hyperintense areas
surrounded by hypointense areas in the bilateral posterior globus
pallidus and putamen at age 42 (Fig. 1B). At age 44, brain CT revealed
symmetrical low density areas in the bilateral basal ganglia (Fig. 2A).
T1-weighted MRI images demonstrated cortical atrophy of the
cerebrum and cerebellum. T2-weighted MRI revealed symmetrical
hyperintense areas surrounded by hypointense areas in the bilateral
posterior globus pallidus and putamen, whereas T2*-weighted and
SWI-MRI revealed hypointense areas in the globus pallidus, putamen,
thalamus, red nucleus, dentate nucleus, and cerebral cortex (Figs. 2
and 3). No spinal cord lesions were observed. 123I-iodoamphetamine
single photon emission tomography (IMP-SPECT) revealed bilateral
mild hypoperfusion of the cerebellum and right hypoperfusion of the
basal ganglia (Fig. 4). Cardiac 123I-metaiodobenzylguanidine (MIBG)represent females. The ﬁlled symbol represents the proband. The symbol “/” represents
band at the age of 42, before onset of neurological symptoms.
Fig. 2.CT andMRI scans of the proband at the age of 44. A. Axial headCT showing symmet-
rical hypodense lesions in the basal ganglia, bilaterally. B. T1-weighted axial MRI image
showing symmetrical hypointense areas in the basal ganglia, revealing the degenerative
and partially cystic nature of the lesions. C. T2-weighted axial MRI image showing
symmetrical hyperintense areas encircled by hypointense areas in the bilateral posterior
globus pallidus and putamen. D–H. T2*-weighted axial MRI images showing hypointense
areas in the dentate nucleus (D), red nucleus (E), globus pallidus, putamen, caudate, thal-
amus (F, G), and cerebral cortex (H), suggesting increaseddeposition of ferritin inmultiple
nuclei. I. T2*-weighted coronal MRI image showing a hypointense rim and a hyperintense
center reminiscent of the “eye of the tiger” sign in the basal ganglia.
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phase: 2.78).3.2. Ferritin measurements
Serum ferritin values in the proband, her parents and brother were
in the normal range (5–204 ng/mL). CSF ferritin levels in the proband
were remarkably low (b1.00 ng/mL, normal range: 6.68±0.93 ng/mL).Fig. 3. Axial susceptibility-weighted images (SWI) show hypointense areas in the globus
pallidus, putamen, caudate, thalamus, red nucleus, dentate nucleus, and motor cortex.3.3. Genetic analysis
The sequence of exons 1, 2 and 3 of the FTL gene and adjacent
intronic sequences were found to be normal. Gel migration analysis of
a PCR product comprising exons 3 and 4 of FTL revealed the presence
of two ampliﬁcation products of 660 and 676 bp in the proband,
whereas the control sample showed only the 660 bp product
(Fig. 5A). DNA sequencing of exon 4 of the FTL gene in the proband re-
vealed a novel mutation in one allele of the FTL gene,
c.468_483dupTGGCCCGGAGGCTGGG (Fig. 5B). The position of the muta-
tionwas near to that of previously reported Japanese [18] and Italian [22]
mutation, c.469_484dupGGCCCGGAGGCTGGGC, shifted onenucleotide to
the 5′ of the previously reportedmutation sequence. To conﬁrm the pres-
ence of themutation found in the proband, the PCRproducts of the ampli-
ﬁcation of exons 3 and 4 were subcloned and recombinant plasmid DNA
isolated and sequenced in both directions. Sequence analysis conﬁrmed
the presence of the 16 bp insertion in the mutant allele (Fig. 5B). As a re-
sult, the predicted mutant polypeptide (p.Leu162TrpfsX24) and the pre-
viously reported mutant polypeptide (p.Leu162ArgfsX24) [18,22] have
different amino acids at codon 162 (tryptophan in p.Leu162TrpfsX24
and arginine in p.Leu162ArgfsX24) but identical sequence and length of
the C-terminus of themutant protein (Fig. 5C). Themutationwas not ob-
served in the proband's parents or her brother, who had normal serum
ferritin levels and unremarkable MRI. Genetic analyses for mutations as-
sociated with spinocerebellar degeneration, such as spinocerebellar
ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17), and
dentatorubral-pallidoluysian atrophy, were negative. No mutations
were observed in the pantothenate kinase 2 (PANK2) gene associated
with pantothenate kinase-associated neurodegeneration (PKAN).
4. Discussion
We report a Japanese female with neuroferritinopathy harboring a
novel mutation in exon 4 of the FTL gene. The proband by age 42
presented with chronic headaches, developing during the next two
years progressive orolingual and arm dystonia, dysarthria, cerebellar
ataxia, pyramidal tract signs, and psychiatric symptoms. Previously
reported individuals with neuroferritinopathy show dystonia and
dysarthria although our proband did not present initially with dystonia;
she gradually exhibited progressive orolingual and limb dystonia over
severalmonths. It has been previously reported that the clinical presen-
tation of the disease may be highly variable not only between families
but also within a family [2–5,14,21,24,25], suggesting that a heteroge-
neous presentation may be a characteristic of neuroferritinopathy.
Although dystonia and dysarthria are the main manifestations of this
condition, the disease cannot be diagnosed only on the basis of clinical
symptoms alone becausemany other clinical features such as pyramidal
signs, cerebellar ataxia, dysautonomia, cognitive impairment, and
psychiatric symptoms may be observed in affected individuals.
The MRI ﬁndings in patients with neuroferritinopathy change with
disease progression according to clinical stage. In the early clinical
stage, hypointense lesions in the basal ganglia are observed on T2*-
weighted images and SWI, particularly in the globus pallidus and puta-
men [12]. With disease progression, the T2* signal loss extends to the
dentate nucleus, red nucleus, substantia nigra, thalamus, caudate
nucleus, and cerebral cortex [19]. In later stages, hyperintense lesions
in the basal ganglia reﬂecting neuronal loss and gliosis due to iron
deposition and ferritin accumulation can be seen on T2-weighted
images. In our case, hypointense lesions on T2* images indicative of
widespread abnormal iron deposition were observed in the globus
pallidus, putamen, caudate, thalamus, red nucleus, dentate nucleus,
and motor cortex. In addition, T2-weighted images revealed mild
cerebral and cerebellar cortical atrophy and symmetrical hyperintense
areas surrounded by hypointense areas in the bilateral posterior globus
pallidus and putamen. The present individual has not revealed the
bilateral large cavities observed in advanced-stage disease, and
Fig. 4. 123I-iodoamphetamine single photon emission tomography (IMP-SPECT) shows hypoperfusion in the bilateral cerebellum and right basal ganglia.
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ganglia on T2-weighted MRI images before symptom onset (Fig. 1B). A
previous study of young carriers of the c.460InsA mutation (6–36 years
old) showed thepresence of hypointense signals onT2*-weighted images
indicative of iron deposition [10], strongly suggesting that iron deposition
may actually begin several decades before the appearance of clinical
symptoms. Coronal T2*-weighted images showed a combination of a
hypointense rim and hyperintense center in the basal ganglia called the
“eye of the tiger” sign, which reﬂects iron deposition in the basal ganglia
on both T2-weighted MRI and T2*-weighted MRI. This sign has been
considered to be pathognomonic of PKAN, but it has also been observed
in other neurodegenerative diseases such as cortical–basal ganglionic
degeneration, multiple system atrophy, progressive supranuclearBA
C
Fig. 5. Genetic analyses of the FTL gene in the proband. A. Analysis of PCR products containing e
band (676 bp) in addition to the normal ampliﬁcation product of 660 bp observed in control in
containing themutant allele (bottom) clearly showing thebeginning (thymine) of the 16-nucleo
indicated on top and the duplicated sequence on bottom. C. Wild-type sequence (top) and m
nucleotide sequences are underlined. The p.Leu162ArgfsX24was previously reported in Japanes
are indicated. Amino acid 162 is in bold.palsy, pure akinesia with gait freezing [9], and neuroferritinopathy [13].
These studies point out a substantial degree of overlap between
neuroferritinopathy and other NBIA diseases in terms of presentation on
T2*-weighted images and SWI. Thus, the diagnosis of neuroferritinopathy
may not be made solely on the basis of neuroimaging. Brain perfusion
studies in the proband (IMP-SPECT) showed asymmetric hypoperfusion
of the cerebellum and the basal ganglia with predominance on the right
side. This ﬁnding is likely to reﬂect the laterality of neurological
symptoms.
Low serum ferritin levels were initially reported in individuals with
the c.460InsA mutation [6]; however, low serum ferritin levels are not
always observed in individuals with neuroferritinopathy [4,6,7,14,16,
18,20–22,25]. Serum ferritin levels in our premenopausal female patientxons 3 and 4 of the FTL gene by agarose gels shows that the proband (P) has an additional
dividuals. B. Direct sequencing of genomic DNA from the proband (top) and cloned DNA
tide duplication (c.468_483dupTGGCCCGGAGGCTGGG).Wild-type nucleotide sequence is
utant sequences (bottom) of the FTL gene showing the 16-bp duplication. The duplicated
e [18] and Italian [22] affected individuals. The predicted C-terminal amino acid sequences
177K. Nishida et al. / Journal of the Neurological Sciences 342 (2014) 173–177were 20 ng/mL (normal range, 5–204 ng/mL), and thus not found to be
signiﬁcantly decreased compared to normal range. Interestingly, CSF
ferritin levels in our patient (b1.00 ng/mL) were signiﬁcantly lower
than normal levels in control individuals (6.68 ± 0.93 ng/mL), and
also lower than ferritin levels in patients with restless leg syndrome
(below 3.5 to 4.1 ng/mL), a disease associated with lower CSF ferritin
levels [8,15]. Further studies will demonstrate whether the measure-
ment of CSF ferritin levels could be used as a novel biomarker for
neuroferritinopathy.
Patients carrying themutation c.469_484dupGGCCCGGAGGCTGGGC
have been described in Japan [18] and Italy [22]. Thismutation is similar
to the one presented here, with one nucleotide difference that causes a
single amino acid change between both mutant ferritins at codon 162
(Fig. 5C); however, we have observed a signiﬁcant degree of variability
in the presentation of the disease between the affected individuals from
the Japanese family (tremorwas themain characteristic symptom) [18],
the Italian patient (behavioral changes and tremor) [22] and our case.
This difference may not be explained at the protein level, since the
general structure of the spherical protein shell seems to be maintained
in mutant ferritin as was seen by X-ray crystallography [1]. All known
mutations associated with the disease may have a similar effect: the
disruption of the 4-fold pores, making the pores unstable and leaky,
and the gradual aggregation of ferritin and iron into a precipitate
mediated by the unraveled and extended mutant C-termini (reviewed
by [17]). Further research will be needed to understanding the effect of
amino acid variations between mutant C-terminal sequences in the
pathogenic process of the disease and the role of genetic and environ-
mental factors in the disease.
In conclusion, ourﬁndings expand the genetic and phenotypic diver-
sity of neuroferritinopathy. The observed clinical features of the disease
in this family further imply the importance of testing for FTLmutations
in patients with distinctive MRI ﬁndings. Further studies will determine
the clinical signiﬁcance of low levels of CSF ferritin and the potential
value of determining CSF ferritin levels for the diagnosis of the disease.
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